Perjeta (Pertuzumab) vs Verzenio/Verzenios (abemaciclib)
Perjeta (Pertuzumab) vs Verzenio/Verzenios (abemaciclib)
Perjeta (pertuzumab) is a monoclonal antibody designed to target the HER2 receptor, a protein overexpressed in some types of breast cancer, and is used primarily in combination with other drugs for the treatment of HER2-positive breast cancer. Verzenio (abemaciclib), on the other hand, is a CDK4/6 inhibitor that interferes with cancer cell division and is used to treat certain types of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. The choice between Perjeta and Verzenio would depend on the specific characteristics of the breast cancer, such as hormone receptor and HER2 status, as well as the patient's previous treatments and overall health condition, and should be made in consultation with an oncologist.
Difference between Perjeta and Verzenio/Verzenios
Metric | Perjeta (Pertuzumab) | Verzenio/Verzenios (abemaciclib) |
---|---|---|
Generic name | Pertuzumab | Abemaciclib |
Indications | HER2-positive breast cancer | HR-positive, HER2-negative breast cancer |
Mechanism of action | HER2 dimerization inhibitor | CDK4 & CDK6 inhibitor |
Brand names | Perjeta | Verzenio |
Administrative route | Intravenous | Oral |
Side effects | Diarrhea, rash, nausea, fatigue, mucosal inflammation, febrile neutropenia | Diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue |
Contraindications | Hypersensitivity to pertuzumab or excipients | Hypersensitivity to abemaciclib or excipients, severe hepatic impairment |
Drug class | Monoclonal antibody | CDK4 & CDK6 inhibitor |
Manufacturer | Genentech (Roche) | Lilly |
Efficacy
Efficacy of Perjeta (Pertuzumab) in Breast Cancer
Perjeta (Pertuzumab) is a monoclonal antibody that targets the HER2 receptor, a protein that can promote the growth of cancer cells. In the treatment of breast cancer, Pertuzumab is specifically used for HER2-positive breast cancers, which are a subtype known for being more aggressive and having a higher likelihood of recurrence. The efficacy of Pertuzumab has been demonstrated in clinical trials when used in combination with trastuzumab and chemotherapy. This combination has been shown to significantly prolong progression-free survival and overall survival in patients with metastatic HER2-positive breast cancer, as well as in the neoadjuvant setting (before surgery), where it can increase the rate of pathological complete response.
Efficacy of Verzenio/Verzenios (Abemaciclib) in Breast Cancer
Verzenio, also known by its generic name abemaciclib, is a CDK4/6 inhibitor used in the treatment of certain types of breast cancer. It is specifically indicated for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. Abemaciclib works by inhibiting the activity of cyclin-dependent kinases 4 and 6 (CDK4/6), which are enzymes that promote cell division and are often overactive in cancer cells. In clinical trials, Verzenio has been shown to significantly improve progression-free survival when used in combination with endocrine therapy, as compared to endocrine therapy alone. Additionally, it has been found to be effective as a monotherapy in patients who have previously received hormone therapy and chemotherapy.
Both Perjeta and Verzenio represent advances in the targeted treatment of breast cancer, offering options for patients with specific subtypes of the disease. Their efficacy in improving survival outcomes underscores the importance of personalized medicine, where treatments are tailored to the unique characteristics of a patient's cancer. Ongoing research continues to refine the use of these medications and explore their full potential in the management of breast cancer.
It is important for patients to discuss the benefits and risks of these treatments with their healthcare providers, considering factors such as the specific characteristics of their breast cancer, prior treatments, and overall health. The selection of treatment is a complex decision that should be made in the context of an individual patient's clinical situation.
Regulatory Agency Approvals
Perjeta
Verzenio/Verzenios
Access Perjeta or Verzenio/Verzenios today
If Perjeta or Verzenio/Verzenios are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us